Aridis Pharmaceuticals, Inc. financial data

Symbol
ARDS on OTC
Industry
Pharmaceutical Preparations
Location
983 University Avenue, Bldg. B, Los Gatos, CA
State of incorporation
Delaware
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 23.8 % -45.8%
Debt-to-equity -147 % +16%
Return On Assets -12.3 % +92.6%
Operating Margin -3.95 % +99.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.6M shares +114%
Common Stock, Shares, Outstanding 44.6M shares +152%
Entity Public Float 12.2M USD -83.2%
Common Stock, Value, Issued 5K USD +150%
Weighted Average Number of Shares Outstanding, Basic 37.4M shares +111%
Weighted Average Number of Shares Outstanding, Diluted 37.4M shares +111%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 22.4M USD +680%
Research and Development Expense 17.4M USD -34.4%
General and Administrative Expense 5.86M USD -21.9%
Costs and Expenses 33.1M USD -25.2%
Operating Income (Loss) -883K USD +97.2%
Net Income (Loss) Attributable to Parent -1.14M USD +96.5%
Earnings Per Share, Basic -0.14 USD/shares +92.7%
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35K USD -98.1%
Accounts Receivable, after Allowance for Credit Loss, Current 417K USD
Assets, Current 4.11M USD -52.4%
Property, Plant and Equipment, Net 511K USD -47.5%
Operating Lease, Right-of-Use Asset 1.07M USD -30%
Other Assets, Noncurrent 327K USD -14.6%
Assets 6.53M USD -46.1%
Accounts Payable, Current 5.41M USD +27.9%
Employee-related Liabilities, Current 435K USD -28.1%
Accrued Liabilities, Current 7.69M USD -9.45%
Contract with Customer, Liability, Current 380K USD -98.1%
Liabilities, Current 17.5M USD -58.3%
Contract with Customer, Liability, Noncurrent 737K USD -13.7%
Operating Lease, Liability, Noncurrent 854K USD -40.3%
Other Liabilities, Noncurrent 3.5M USD +816%
Liabilities 18.3M USD -59.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 7.79M USD
Retained Earnings (Accumulated Deficit) -190M USD -2.26%
Stockholders' Equity Attributable to Parent -11.8M USD +67.1%
Liabilities and Equity 6.53M USD -46.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4M USD +60.6%
Net Cash Provided by (Used in) Financing Activities 263K USD -94.1%
Net Cash Provided by (Used in) Investing Activities -21K USD +93.7%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44.6M shares +152%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.74M USD +34.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 535K USD -82.9%
Deferred Tax Assets, Valuation Allowance 34.1M USD +19.4%
Deferred Tax Assets, Gross 34.1M USD +19.4%
Operating Lease, Liability 1.43M USD -26.9%
Depreciation 539K USD +51%
Payments to Acquire Property, Plant, and Equipment 21K USD -93.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6.65M USD
Lessee, Operating Lease, Liability, to be Paid 1.53M USD -29%
Property, Plant and Equipment, Gross 2.76M USD -5.45%
Operating Lease, Liability, Current 576K USD +9.51%
Lessee, Operating Lease, Liability, to be Paid, Year Two 646K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 158K USD -74.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 97K USD -50%
Lessee, Operating Lease, Liability, to be Paid, Year Three 666K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 23.4M USD +3.63%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 60M shares 0%
Unrecognized Tax Benefits 1.3M USD +38%
Lessee, Operating Lease, Liability, to be Paid, Year Four 57K USD
Additional Paid in Capital 171M USD +11.3%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 5K USD -16.7%
Depreciation, Depletion and Amortization 87K USD -33.6%
Deferred Tax Assets, Net of Valuation Allowance 2.3M USD
Share-based Payment Arrangement, Expense 862K USD -52.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%